Modality
mAb
MOA
WEE1i
Target
Cl18.2
Pathway
Cell Cycle
ALLGBMPSP
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
Jun 2022
→ Dec 2025
Phase 1Current
NCT04087308
758 pts·PSP
2022-06→2025-12·Terminated
758 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-12-273mo agoInterim· PSP
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P1
Termina…
Catalysts
Interim
2025-12-27 · 3mo ago
PSP
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04087308 | Phase 1 | PSP | Terminated | 758 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-611 | Madrigal Pharma | Approved | CGRP |